• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

酰基辅酶A胆固醇酰基转移酶抑制剂作为抗动脉粥样硬化药物:化合物与作用机制

ACAT inhibitors as antiatherosclerotic agents: compounds and mechanisms.

作者信息

Matsuda K

机构信息

Cardiovascular & Atherosclerosis Research Laboratories, Yamanouchi Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co. Ltd., Ibaraki Pref., Japan.

出版信息

Med Res Rev. 1994 May;14(3):271-305. doi: 10.1002/med.2610140302.

DOI:10.1002/med.2610140302
PMID:8007738
Abstract

Atherosclerosis is a major death cause in western industrialized countries. A diagnosing system, medical prevention, and treatment of atherosclerosis is not sufficient so far. A direct acting antiatherosclerotic agent is eagerly waited. ACAT inhibitor approach could provide such an agent. In the formation of atherosclerosis, cholesteryl esters, which are the lipids which accumulate in atheromatous plaques by an aid of macrophages and smooth muscle cells, forming foam cells, may play an important role. ACAT enzyme is responsible for the acylation of cholesterol to cholesteryl esters, a transformation which can be essential in not only cholesteryl esters accumulation at arterial walls but also the absorption of cholesterol in the intestine and the excretion of cholesterol in the liver. From these points, ACAT inhibitors might work against atherosclerosis in three different ways: first, cholesteryl ester accumulation inhibition at arterial walls could be a direct antiatherosclerotic effect; second, cholesterol absorption inhibition at the intestine; and third, cholesterol excretion acceleration at the liver, while the later two effects would result in a reduction of blood cholesterol level--a major risk factor of atherosclerosis. Taking account of this discussion, the ACAT inhibitors would be potent antiatherosclerotic agents. Medicinal research has been contributing full strength to produce an ultimate compound. These efforts should provide a drug which will be useful to patients.

摘要

动脉粥样硬化是西方工业化国家的主要死因。到目前为止,动脉粥样硬化的诊断系统、医学预防和治疗都还不够完善。人们急切地期待着一种直接作用的抗动脉粥样硬化药物。酰基辅酶A:胆固醇酰基转移酶(ACAT)抑制剂方法有望提供这样一种药物。在动脉粥样硬化的形成过程中,胆固醇酯(一种在巨噬细胞和平滑肌细胞的作用下在动脉粥样硬化斑块中积聚、形成泡沫细胞的脂质)可能起重要作用。ACAT酶负责将胆固醇酰化为胆固醇酯,这一转化不仅对动脉壁上胆固醇酯的积聚至关重要,而且对肠道中胆固醇的吸收和肝脏中胆固醇的排泄也必不可少。基于这些观点,ACAT抑制剂可能通过三种不同方式对抗动脉粥样硬化:第一,抑制动脉壁上胆固醇酯的积聚可产生直接的抗动脉粥样硬化作用;第二,抑制肠道对胆固醇的吸收;第三,加速肝脏中胆固醇的排泄,而后两种作用会导致血液胆固醇水平降低——动脉粥样硬化的一个主要危险因素。考虑到上述讨论,ACAT抑制剂可能是有效的抗动脉粥样硬化药物。药物研究一直在全力以赴研发出最终的化合物。这些努力应该会提供一种对患者有用的药物。

相似文献

1
ACAT inhibitors as antiatherosclerotic agents: compounds and mechanisms.酰基辅酶A胆固醇酰基转移酶抑制剂作为抗动脉粥样硬化药物:化合物与作用机制
Med Res Rev. 1994 May;14(3):271-305. doi: 10.1002/med.2610140302.
2
[Development of new antiatherosclerotic agents--ACAT inhibitors and CETP inhibitors].
Nihon Rinsho. 1999 Dec;57(12):2842-7.
3
Acyl-coenzyme A:cholesterol acyltransferase inhibitors for controlling hypercholesterolemia and atherosclerosis.用于控制高胆固醇血症和动脉粥样硬化的酰基辅酶A:胆固醇酰基转移酶抑制剂。
Curr Opin Investig Drugs. 2003 Sep;4(9):1095-9.
4
Potential role of acyl-coenzyme A:cholesterol transferase (ACAT) Inhibitors as hypolipidemic and antiatherosclerosis drugs.酰基辅酶A:胆固醇转移酶(ACAT)抑制剂作为降血脂和抗动脉粥样硬化药物的潜在作用。
Pharm Res. 2005 Oct;22(10):1578-88. doi: 10.1007/s11095-005-6306-0. Epub 2005 Sep 22.
5
Acyl coenzyme A:cholesterol acyltransferase inhibition: potential atherosclerosis therapy or springboard for other discoveries?酰基辅酶A:胆固醇酰基转移酶抑制作用:是潜在的动脉粥样硬化治疗方法还是其他发现的跳板?
Expert Opin Investig Drugs. 2002 Nov;11(11):1519-27. doi: 10.1517/13543784.11.11.1519.
6
Human acyl-CoA:cholesterol acyltransferase (ACAT) and its potential as a target for pharmaceutical intervention against atherosclerosis.人酰基辅酶A:胆固醇酰基转移酶(ACAT)及其作为抗动脉粥样硬化药物干预靶点的潜力。
Acta Biochim Biophys Sin (Shanghai). 2006 Mar;38(3):151-6. doi: 10.1111/j.1745-7270.2006.00154.x.
7
Acyl coenzyme A:cholesterol acyltransferase inhibitors as hypolipidemic and antiatherosclerotic drugs.酰基辅酶A:胆固醇酰基转移酶抑制剂作为降血脂和抗动脉粥样硬化药物
Methods Find Exp Clin Pharmacol. 2004 Sep;26(7):563-86. doi: 10.1358/mf.2004.26.7.863738.
8
Inhibition of acyl-CoA cholesterol acyltransferase by F12511 (Eflucimibe): could it be a new antiatherosclerotic therapeutic?F12511(依氟米贝)对酰基辅酶A胆固醇酰基转移酶的抑制作用:它会成为一种新型抗动脉粥样硬化治疗药物吗?
Cardiovasc Ther. 2008 Spring;26(1):65-74. doi: 10.1111/j.1527-3466.2007.00030.x.
9
Preferential pharmacological inhibition of macrophage ACAT increases plaque formation in mouse and rabbit models of atherogenesis.对巨噬细胞ACAT的选择性药理抑制会增加动脉粥样硬化小鼠和兔模型中的斑块形成。
Atherosclerosis. 2001 Apr;155(2):359-70. doi: 10.1016/s0021-9150(00)00599-2.
10
Inhibition of acyl coenzyme A-cholesterol acyltransferase: a possible treatment of atherosclerosis?抑制酰基辅酶A胆固醇酰基转移酶:动脉粥样硬化的一种可能治疗方法?
Curr Atheroscler Rep. 2002 Jan;4(1):65-70. doi: 10.1007/s11883-002-0064-9.

引用本文的文献

1
Urea production via photocatalytic coupling of mixed gases (CO/NH) using Mo(MnO) supported on Ce-BTC as nano-composite catalyst.使用负载在Ce-BTC上的Mo(MnO)作为纳米复合催化剂,通过混合气体(CO/NH)的光催化偶联生产尿素。
Sci Rep. 2024 Jul 6;14(1):15608. doi: 10.1038/s41598-024-65363-z.
2
Iron-catalyzed urea synthesis: dehydrogenative coupling of methanol and amines.铁催化尿素合成:甲醇与胺的脱氢偶联反应
Chem Sci. 2018 Apr 9;9(16):4003-4008. doi: 10.1039/c8sc00775f. eCollection 2018 Apr 28.
3
Biochemical and histopathological study in rats intoxicated with carbontetrachloride and treated with camel milk.
四氯化碳中毒大鼠并用骆驼奶治疗的生化和组织病理学研究
Springerplus. 2013 Dec;2(1):57. doi: 10.1186/2193-1801-2-57. Epub 2013 Feb 18.
4
Macrophage cholesterol homeostasis and metabolic diseases: critical role of cholesteryl ester mobilization.巨噬细胞胆固醇稳态与代谢性疾病:胆固醇酯动员的关键作用
Expert Rev Cardiovasc Ther. 2011 Mar;9(3):329-40. doi: 10.1586/erc.11.16.
5
Macrophage cholesteryl ester mobilization and atherosclerosis.巨噬细胞胆固醇酯的动员与动脉粥样硬化
Vascul Pharmacol. 2010 Jan-Feb;52(1-2):1-10. doi: 10.1016/j.vph.2009.10.002. Epub 2009 Oct 28.
6
Direct effect of an acyl-CoA:cholesterol acyltransferase inhibitor, F-1394, on atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice.酰基辅酶A:胆固醇酰基转移酶抑制剂F-1394对载脂蛋白E和低密度脂蛋白受体双敲除小鼠动脉粥样硬化的直接作用
Br J Pharmacol. 2001 Aug;133(7):1005-12. doi: 10.1038/sj.bjp.0704160.
7
Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages.巨噬细胞中缺乏ACAT1的低密度脂蛋白受体缺失小鼠动脉粥样硬化加剧。
J Clin Invest. 2001 Jan;107(2):163-71. doi: 10.1172/JCI10310.
8
Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA:cholesterol acyltransferase 1.缺乏酰基辅酶A:胆固醇酰基转移酶1的高脂血症小鼠中的大量黄瘤病和动脉粥样硬化病变组成改变。
J Clin Invest. 2000 Mar;105(6):711-9. doi: 10.1172/JCI9021.
9
Pharmacokinetic properties of YM17E, an inhibitor of acyl coenzyme A: cholesterol acyl transferase, and serum cholesterol levels in healthy volunteers.
Eur J Clin Pharmacol. 1997;51(5):399-406. doi: 10.1007/s002280050221.